Streetbeat News

Revenues

AURA

Aura Biosciences reported a Q2 2024 GAAP EPS of $(0.41), beating the estimate of $(0.46). The company has cash, cash equivalents, and marketable securities totaling $187.4 million, which are expected to fund operations into the second half of 2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:28 pm

LLY

Eli Lilly (NYSE: LLY) reported strong Q2 earnings, with revenue of $11.3 billion, up 36% YoY, surpassing estimates. The growth was driven by increased sales of diabetes and weight loss drugs, particularly Mounjaro, Zepbound, Verzenio, Taltz, and Jardiance. The company raised its 2024 sales and EPS guidance, reflecting confidence in continued strong performance.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 12:26 pm

FHTX

Foghorn Therapeutics reported its Q2 2024 financial results, with a GAAP EPS of $(0.45) beating the estimate of $(0.47). Sales were $6.888M, surpassing the $6.094M estimate. The company has $285.2M in cash, cash equivalents, and short-term investments as of June 30, 2024, extending its expected cash runway into 2027.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:25 pm

PRQR

ProQR Therapeutics reported a Q1 2024 GAAP EPS of €(0.03), beating the estimate of €(0.11). However, sales of €6.305M missed the estimate of €11.460M. The company has a cash position of €96.2M as of the end of Q2, providing a runway into mid-2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:22 pm

FWONA

Liberty Formula One Group (NASDAQ:FWONA) reported Q2 sales of $988.00 million, beating the analyst consensus estimate of $984.25 million by 0.38%. This represents a 36.46% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:21 pm

FWONA

Liberty Formula One Group reported Q2 sales of $988 million, surpassing the estimated $984.25 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:19 pm

BATRA

Liberty Braves Group (NASDAQ:BATRA) reported Q2 earnings per share of $0.46, beating the analyst estimate of $0.32 by 43.75%. However, sales of $282.88 million missed the estimate of $285.85 million by 1.04%. Compared to the same period last year, EPS increased by 39.39% and sales by 4.77%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:19 pm

ITOS

ITeos Therapeutics reported a Q2 2024 GAAP EPS of $(0.18), significantly beating the estimated $(1.04). The company also announced a pro forma cash and investment balance of $714.4M as of June 30, 2024, which is expected to provide financial runway through 2027.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:17 pm

LTRPA

Liberty TripAdvisor Holdings (NASDAQ: LTRPA) reported a significant increase in Q2 earnings per share (EPS) to $0.63, up 384.62% from $0.13 YoY. Sales also saw a slight increase to $497.00 million from $494.00 million YoY.

Portfolio Pulse from totan@benzinga.com

August 08, 2024 | 12:15 pm

VERV

Verve Therapeutics reported a Q2 2024 GAAP EPS of $(0.59), beating the estimate of $(0.71). Sales were $6.692M, surpassing the $2.030M estimate. The company has $575.9M in cash, cash equivalents, and marketable securities, providing a cash runway into late 2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:14 pm